Original Query: ALL
Previous Study | Return to List | Next Study

Role of the Autonomic Nervous System in HIV-Lipodystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00149097
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : May 12, 2008
HW&J Hector-Stiftung
Information provided by:
Hannover Medical School

Brief Summary:
The study aims to characterise the influence of the autonomic nervous system activity on the development of the lipodystrophy syndrome in HIV-infected patients by measuring heart rate variability and various metabolic pathways in HIV patients receiving highly active antiretroviral therapy.

Condition or disease
HIV Infections Lipodystrophy-Syndrome

Study Type : Observational
Actual Enrollment : 54 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Autonomic Nervous System Activity in the Pathogenesis of the Lipodystrophy Syndrome in HIV-Infected Patients.
Study Start Date : March 2005
Study Completion Date : January 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Biospecimen Retention:   Samples Without DNA
Serum and Plasma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with confirmed HIV infection and no active opportunistic infection during the last 2 months.

Inclusion Criteria:

  • HIV-infection
  • Age above 18 years
  • No AIDS defining event during last 6 months
  • No infection during last 6 weeks
  • No concommitant drug interfering with insulin sensitivity and ANS-activity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00149097

Hannover Medical School
Hannover, Germany, 30625
Sponsors and Collaborators
Hannover Medical School
HW&J Hector-Stiftung
Principal Investigator: Georg MN Behrens, MD Hannover Medical School

Responsible Party: Prof. Georg Behrens, Hannover Medical School Identifier: NCT00149097     History of Changes
Other Study ID Numbers: ANS-M26
First Posted: September 8, 2005    Key Record Dates
Last Update Posted: May 12, 2008
Last Verified: May 2008

Additional relevant MeSH terms:
HIV Infections
Pathologic Processes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Skin Diseases, Metabolic
Skin Diseases
Lipid Metabolism Disorders
Metabolic Diseases